Mr. Spoor was previously President, Chief Executive Officer and a member of the board of directors of Fluoropharma Medical, Inc. from February 14, 2011 until December 31, 2015.  Mr. Spoor was the CFO for Sunstone BioSciences, a nanotechnology firm and as a strategy consultant at Oliver Wyman working with biotechnology, pharmaceutical, medical device and health insurance companies. Mr. Spoor was an equity research analyst at J.P. Morgan and Credit Suisse covering the biotechnology and medical device industries. Prior to his career on Wall Street, Mr. Spoor worked in the pharmaceutical industry spending 11 years with Amersham /GE Healthcare where he worked in 7 countries in a variety of commercial and strategy roles.  Mr. Spoor holds a Pharmacy degree from the University of Toronto as well as an M.B.A. from Columbia University with concentrations in finance and accounting.

PhD, Chief Scientific Officer

Dr. Dupret joins after serving as President of ProteaBio Europe, a wholly-owned European subsidiary of Protea Biosciences. He joined Protea Biosciences in October 2008 to launch and manage ProteaBio Europe. Previously, Daniel founded Proteus SA in 1998 and served as its President and CEO from 1998 to 2007. He founded Appligene SA in 1985 and served as CSO, President, and CEO, respectively, until 1998. From 1982 to 1985, he served as Project Leader at Transgene SA. In parallel to his Biotechnology career, Mr. Dupret was an expert for the French government and the European commission in grant commission and funding of young biotech companies. From 2003 to 2007, he served as President of the Board of the University of Nîmes. Dr. Dupret received his PhD. at the Medical University of Strasbourg.

Chief Financial Officer

Mr. Shenouda has over 25 years of experience in the pharmaceutical and securities industries. Most recently, Mr. Shenouda was the Head of Business Development and Licensing at Retrophin, Inc. Prior to that, he served as the Head of East Coast Operations at Blueprint Life Science Group, a strategic investor relations consultancy. Mr. Shenouda spent the bulk of his career as an equity analyst with senior level positions at Stifel Nicolaus, UBS and JP Morgan, covering a broad range of small and large cap biotechnology companies. Mr. Shenouda started his sell-side career with Citigroup and Bear Stearns where his coverage universe focused on U.S and European pharmaceutical companies. Before entering Wall Street, Mr. Shenouda was a management consultant with PricewaterhouseCoopers' Pharmaceutical Consulting practice and also spent time in pharmaceutical sales, having worked as a hospital representative and managed care specialist for Abbott Laboratories' Pharmaceutical Products Division. Mr. Shenouda earned a B.S. in pharmacy from St. John's University and is a registered pharmacist in New Jersey and California. He also received an M.B.A. from Rutgers University Graduate School of Management.

PhD, R&D, Programs Director

Dr. Lebreton joined AzurRx in June 2015 after serving as R&D Programs Director at Eyevensys from 2013-2015.  Previously he served as Therapeutic Area Leader in occular diseeases at Abbott (formerly Solvay Pharmaceuticals) from 2009-2013 and as the Global R&D Programs Director at Solvay Pharmaceuticals from 2007-2009.  From 2001-2007 he held several roles at Laboratoires Fournier including Research Program Manager, Chemistry Group Leader/Senior Medicinal Chemist, and Chemistry Lab Manager from 2001-2007.  Dr. Lebreton received his PhD in pharmaco-chemistry at the University of Paris VII.

PhD, Head of Laboratory

Dr. Schué joins after serving as Project Leader for the development of a new therapeutic protein (AZX1101), to be associated with antibiotics, at ProteaBio Europe since 2009. He is also involved in the API aspects (cell banking, API production and characterization) of the MS1819 pharmaceutical development. Dr. Schué graduated first as a chemical engineer at “Ecole Nationale Supérieure de Chimie de Montpellier” (ENSCM), Montpellier with specialization in biochemistry and molecular biology and then with a PhD in molecular microbiology at the University of Birmingham, UK. With three years of post-doctoral positions at “Commissariat à l’Energie Atomique” (CEA) at Cadarache, and CNRS, Marseille, he has gained solid expertise in biotechnology (recombinant protein expression and purification) and enzymology (molecular and structural characterizations). Dr. Schué received his Ph.D. in molecular microbiology at the University of Birmingham in the UK.

PhD, Director of Research and Development

Dr. Leblond joins after serving as the R&D director for the development of pharmaceutical drug products at ProteaBio Europe since 2009. Yves has more than 25 years’ experience in multi-national pharmaceutical companies. From 2002 to 2009, he held the position of R&D director for LMS Laboratories. From 1991 until 2002, he was the head of the non-clinical drug safety department for the Fournier Group. From 1986 to 1991, he served as the head coordinator in the drug safety department for Synthelabo Group. From 1984 to 1986, Yves was the head of the preclinical department at Boerhinger Laboratories. Yves has expertise in pharmacology/toxicology and pharmacokinetic/metabolism in addition to multiple projects managed (more than 6 international products developed) in various therapeutic areas such as cardiovascular, anti-inflammatory, immunosuppressive and gastro-intestinal diseases. Yves received his PhD. from University Paris XI.

Vice President for Finance and Business Development

Mr. Krusin is an experienced executive with over 15 years of business development, strategic marketing, financing and operating experience in the healthcare, financial services, and consulting sectors. Prior to joining AzurRx BioPharma as VP for Business Development  in 2012, Mr. Krusin was Director of Business Development at Clewed (a business services and investment partnership); an Experienced Commercial Leader at GE Capital in its Global Sponsor Finance, Healthcare Financial Services, and Capital Solutions units; Vice President of Marketing & Sales and Director of Business Development at Electro-Optical Sciences (now MelaSciences); and an analyst in the Emerging Markets Strategic Planning Group at Citigroup. Mr. Krusin received a MBA from Columbia Business School in finance and marketing, a MPhil. in political economy from Oxford University, and a BA in international relations from Swarthmore College.